Header Logo

Connection

SUSAN HILSENBECK to Aged

Back to Details
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Aged.
SUSAN HILSENBECK
Connection Strength
0.415
Aged
  1. To share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med. 2011 Nov; 13(11):948-55.
    View in: PubMed
    Score: 0.028
  2. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005 Jan; 89(2):173-8.
    View in: PubMed
    Score: 0.017
  3. Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. Clin Colorectal Cancer. 2020 06; 19(2):e49-e57.
    View in: PubMed
    Score: 0.012
  4. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
    View in: PubMed
    Score: 0.012
  5. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res. 2020 02 15; 26(4):821-827.
    View in: PubMed
    Score: 0.012
  6. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. Breast Cancer Res Treat. 2019 Sep; 177(2):427-435.
    View in: PubMed
    Score: 0.012
  7. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
    View in: PubMed
    Score: 0.011
  8. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
    View in: PubMed
    Score: 0.011
  9. Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clin Breast Cancer. 2018 02; 18(1):78-87.
    View in: PubMed
    Score: 0.011
  10. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat. 2017 Nov; 166(1):277-287.
    View in: PubMed
    Score: 0.010
  11. Retrospective review of genomic testing in breast cancer: Does it improve outcome? Breast Cancer Res Treat. 2017 May; 163(1):191-195.
    View in: PubMed
    Score: 0.010
  12. Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017 02 14; 317(6):596-605.
    View in: PubMed
    Score: 0.010
  13. Stereotactic Biopsy of Segmental Breast Calcifications: Is Sampling of Anterior and Posterior Components Necessary? Acad Radiol. 2016 06; 23(6):682-6.
    View in: PubMed
    Score: 0.009
  14. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1688-98.
    View in: PubMed
    Score: 0.008
  15. Pediatric data sharing in genomic research: attitudes and preferences of parents. Pediatrics. 2014 Apr; 133(4):690-7.
    View in: PubMed
    Score: 0.008
  16. Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. Chest. 1993 Nov; 104(5):1445-51.
    View in: PubMed
    Score: 0.008
  17. Participants' recall and understanding of genomic research and large-scale data sharing. J Empir Res Hum Res Ethics. 2013 Oct; 8(4):42-52.
    View in: PubMed
    Score: 0.008
  18. Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol. 1993 Aug; 16(4):301-9.
    View in: PubMed
    Score: 0.008
  19. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol. 2013 May 10; 31(14):1726-31.
    View in: PubMed
    Score: 0.008
  20. Estimation of completeness and adjustment of age-specific and age-standardized incidence rates. Biometrics. 1992 Dec; 48(4):1249-62.
    View in: PubMed
    Score: 0.008
  21. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat. 2012 Dec; 136(3):795-804.
    View in: PubMed
    Score: 0.007
  22. The increasing recognition of adenosquamous lung carcinoma (1977-1986). Am J Clin Oncol. 1992 Aug; 15(4):356-62.
    View in: PubMed
    Score: 0.007
  23. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer. 2012 Jun 13; 12:243.
    View in: PubMed
    Score: 0.007
  24. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol. 1992 May; 45(2):142-6.
    View in: PubMed
    Score: 0.007
  25. Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics. 2012; 15(2):106-14.
    View in: PubMed
    Score: 0.007
  26. Assessment of the learning curve for pancreaticoduodenectomy. Am J Surg. 2012 Jun; 203(6):684-90.
    View in: PubMed
    Score: 0.007
  27. Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat. 2011 Aug; 129(1):221-7.
    View in: PubMed
    Score: 0.007
  28. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011 Jun 15; 17(12):4177-86.
    View in: PubMed
    Score: 0.007
  29. The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):463-72.
    View in: PubMed
    Score: 0.007
  30. Long-term survival in stage III and IV ovarian cancer. Arch Gynecol Obstet. 1991; 249(2):87-93.
    View in: PubMed
    Score: 0.007
  31. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011 Jan 10; 29(2):166-73.
    View in: PubMed
    Score: 0.007
  32. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res. 2010 Nov 01; 70(21):8517-25.
    View in: PubMed
    Score: 0.006
  33. Drain data to predict clinically relevant pancreatic fistula. HPB (Oxford). 2010 Sep; 12(7):472-81.
    View in: PubMed
    Score: 0.006
  34. Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol. 2009 Nov 12; 2:47.
    View in: PubMed
    Score: 0.006
  35. Value of pancreatic resection for cancer metastatic to the pancreas. J Surg Res. 2009 Oct; 156(2):189-98.
    View in: PubMed
    Score: 0.006
  36. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008 May; 247(5):732-8.
    View in: PubMed
    Score: 0.005
  37. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008 May 07; 100(9):672-9.
    View in: PubMed
    Score: 0.005
  38. Effect of BioGlue on the incidence of pancreatic fistula following pancreas resection. J Gastrointest Surg. 2008 May; 12(5):882-90.
    View in: PubMed
    Score: 0.005
  39. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.
    View in: PubMed
    Score: 0.005
  40. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
    View in: PubMed
    Score: 0.005
  41. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
    View in: PubMed
    Score: 0.005
  42. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94.
    View in: PubMed
    Score: 0.004
  43. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
    View in: PubMed
    Score: 0.004
  44. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003 Dec; 4(5):348-53.
    View in: PubMed
    Score: 0.004
  45. Medical complications and outcomes after hip fracture repair. Arch Intern Med. 2002 Oct 14; 162(18):2053-7.
    View in: PubMed
    Score: 0.004
  46. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002 Jun 01; 20(11):2701-12.
    View in: PubMed
    Score: 0.004
  47. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol. 2000 May; 18(9):1906-13.
    View in: PubMed
    Score: 0.003
  48. Laparoscopic cholecystectomy and cirrhosis: a case-control study of outcomes. Liver Transpl. 2000 May; 6(3):340-4.
    View in: PubMed
    Score: 0.003
  49. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
    View in: PubMed
    Score: 0.003
  50. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998 Mar 01; 91(5):1533-41.
    View in: PubMed
    Score: 0.003
  51. A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion. Invest New Drugs. 1998; 16(1):57-67.
    View in: PubMed
    Score: 0.003
  52. Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett. 1997 Jun 24; 116(2):177-83.
    View in: PubMed
    Score: 0.003
  53. Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs. 1997; 15(4):361-4.
    View in: PubMed
    Score: 0.002
  54. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.
    View in: PubMed
    Score: 0.002
  55. Risk of pulmonary complications after elective abdominal surgery. Chest. 1996 Sep; 110(3):744-50.
    View in: PubMed
    Score: 0.002
  56. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
    View in: PubMed
    Score: 0.002
  57. Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery. J Gen Intern Med. 1995 Dec; 10(12):671-8.
    View in: PubMed
    Score: 0.002
  58. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer. 1995 Nov 15; 76(10 Suppl):1978-86.
    View in: PubMed
    Score: 0.002
  59. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.
    View in: PubMed
    Score: 0.002
  60. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol. 1993 Nov; 11(11):2194-204.
    View in: PubMed
    Score: 0.002
  61. Five-drug antiemetic combination for cisplatin chemotherapy. Cancer Invest. 1992; 10(3):191-9.
    View in: PubMed
    Score: 0.002
  62. Lung carcinoma in 1,336 patients. Am J Clin Oncol. 1991 Dec; 14(6):496-508.
    View in: PubMed
    Score: 0.002
  63. Reactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: a reevaluation of the benign hemophagocytic proliferations. Hum Pathol. 1988 Jun; 19(6):705-12.
    View in: PubMed
    Score: 0.001
  64. Toxicity of FED chemotherapy in non-small-cell lung cancer. Am J Clin Oncol. 1987 Dec; 10(6):499-506.
    View in: PubMed
    Score: 0.001
  65. Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer. Breast Cancer Res Treat. 1984; 4(4):283-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.